Medexus Pharmaceuticals Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
7/10
|
15.77 | 117.69 | -86.6% | 15.77 | 0% |
| P/S |
|
0.1781 | 8.16 | -97.82% |
|
|
| P/BV |
|
0.8577 | 3.37 | -74.55% |
|
|
| P/FCF |
|
0 | 160.84 | -100% |
|
|
| Ev/Ebitda |
|
5.21 | 52.39 | -90.06% |
|
|
| Ev/S |
|
0.7055 | 6.96 | -89.87% |
|
|
| Ev/FCF |
|
-42.23 | 142.77 | -129.58% |
|
|
| E/P |
|
0 | 1.47 | -100% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
4/10
|
13.55 | 24.93 | -45.66% | 4.55 | 197.96% |
| ROE |
|
5.44 | 12.96 | -58.03% |
|
|
| ROA |
|
0.7568 | 6.09 | -87.58% |
|
|
| ROIC |
|
0 | 15.56 | -100% |
|
|
| ROS |
|
1.13 | 12.55 | -91% |
|
|
| ROCE |
|
37.82 | 16.88 | 124% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
1/10
|
4.79 | 143.57 | -96.67% | 3.66 | 30.68% |
| Nеt Debt/Ebitda |
|
3.89 | -5.05 | -177.04% |
|
|
| Debt/Ratio |
|
0.4344 | 0.4053 | 7.18% |
|
|
| Debt/Equity |
|
77.96 | 11.8 | 560.88% |
|
|
| Debt/Net Income |
|
57.4 | 147.58 | -61.11% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 1.73 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 1.07 | -100% |
|
|
| DSI |
|
0 | 0.7807 | -100% |
|
|
| Average dividend growth |
|
0 | -79.6 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 2.81 | -100% |
|
|
| Average percentage for payments |
|
0 | 247.07 | -100% |
|
|
| Difference from average difference in sector |
|
-1.73 |
|
|
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % |
|---|---|---|---|---|
| Growth impulse Revenue 5 years |
7/10
|
51.95 | 180.62 | -71.24% |
| Growth impulse Ebitda 5 years |
|
9111.32 | 201.95 | 4411.67% |
| Growth impulse Net Income 5 years |
|
-96.55 | 160.03 | -160.33% |
| Growth impulse FCF 5 years |
|
-627.09 | 118.65 | -628.52% |
| Growth impulse EPS 5 years |
|
-97.97 | 280.49 | -134.93% |
IP Score
3.26/10
